Oxford Launches First Human Trial of Bundibugyo Ebola Vaccine Candidate

The University of Oxford has launched the world’s first human clinical trial for a vaccine candidate designed to combat the Bundibugyo strain of the Ebola virus. This initiative aims to address a growing public health crisis as the virus spreads through the Democratic Republic of the Congo (DRC) and poses a significant risk to neighboring Uganda.

The early-stage Phase I trial, referred to as BD-Ebov, is designed to assess the safety and immune response of the vaccine, known as ChAdOx1 BDBV. The study will involve 50 healthy adult volunteers aged 18 to 55 in Oxford. Recruitment is currently underway, and vaccinations are expected to begin in the coming weeks following final regulatory approvals.

Vaccine Development and Technology

The vaccine was developed by scientists at Oxford’s Vaccine Group and the Pandemic Sciences Institute. The candidate utilizes the ChAdOx viral vector platform, the same technology employed in the creation of the Oxford/AstraZeneca COVID-19 vaccine. Researchers believe that utilizing this established platform has allowed for a rapid development timeline, enabling the project to reach human trials in a matter of weeks.

The development process has been characterized by significant international collaboration. The Serum Institute of India, a key partner in the program, has already manufactured and stockpiled approximately 620,000 doses of the vaccine candidate to ensure immediate availability should large-scale clinical trials or emergency deployment become necessary. The institute also provided 4,000 investigational doses specifically for the current Phase I study.

Addressing the Outbreak

The Bundibugyo strain currently lacks any approved vaccines or specific treatments, making the development of an effective countermeasure a critical priority. The World Health Organization (WHO) declared the outbreak a public health emergency of international concern, and the organization has recommended that the ChAdOx1 BDBV vaccine be prioritized for clinical evaluation.

Data regarding the current epidemic highlights the severity of the situation. According to official reports, there are 1,926 confirmed cases of the virus, resulting in 702 deaths. The outbreak has been spreading across several provinces in the DRC, including Ituri, North Kivu, South Kivu, Haut-Uele, and Tshopo. Due to its long and porous border with the DRC, Uganda remains at high risk.

International Partnership and Future Trials

Financial backing for the project is provided by the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed an initial investment of up to $8.6 million to support the vaccine’s development and testing.

“The ongoing Bundibugyo ebolavirus outbreak continues to devastate affected communities, underlining the urgent need for effective vaccines and treatments,” said Professor Teresa Lambe, the study’s lead scientific investigator.

Parallel efforts are underway to expand clinical testing. Researchers are collaborating with several institutions, including the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit, to prepare for subsequent trials in Africa. In Masaka, Uganda, a separate group of over 100 volunteers is expected to participate in trials. These participants will be divided into groups to receive either a single dose, two doses, or to assess potential cross-reactivity for individuals previously vaccinated against the Zaire strain of Ebola.

Projected Timeline and Objectives

The current UK trial will monitor volunteers for one year, though scientists anticipate determining whether the vaccine offers effective protection relatively quickly. If the results of the initial Phase I testing are positive, organizers plan to move toward larger, late-stage Phase 3 trials. These studies, which could potentially begin as early as October, would focus on individuals at direct risk of infection and are a necessary step toward achieving emergency-use authorization or full regulatory approval.

The project partners—including Oxford, the Serum Institute, and CEPI—have emphasized that ensuring affordable and rapid access for the most vulnerable countries remains a core objective of the initiative. By evaluating multiple vaccine options, including the rVSV Bundibugyo candidate being developed by the International AIDS Vaccine Initiative, health experts hope to strengthen the global response to this and future public health emergencies.

Find more reporting in our Health section.